Mariner
DNA icon

Mariner’s Ginkgo Bioworks DNA Stock Holding History

Mariner’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$667K Buy
67,359
+7,060
+12% +$59K ﹤0.01% 2264
2026
Q1 		$370K Buy
60,299
+6,824
+13% +$56.8K ﹤0.01% 2698
2025
Q4 		$444K Buy
53,475
+604
+1% +$6.5K ﹤0.01% 2518
2025
Q3 		$771K Buy
52,871
+2,781
+6% +$33.3K ﹤0.01% 2097
2025
Q2 		$564K Buy
50,090
+2
+0% +$15 ﹤0.01% 2230
2025
Q1 		$286K Buy
50,088
+88
+0.2% +$897 ﹤0.01% 2672
2024
Q4 		$491K Hold
50,000
– – ﹤0.01% 2205
2024
Q3 		$408K Sell
50,000
-2,585
-5% -$25.9K ﹤0.01% 2308
2024
Q2 		$703K Buy
52,585
+71
+0.1% +$2.12K ﹤0.01% 1770
2024
Q1 		$2.44M Buy
52,514
+255
+0.5% +$13.2K 0.01% 1007
2023
Q4 		$3.53M Buy
52,259
+333
+0.6% +$20.4K 0.01% 814
2023
Q3 		$3.76M Buy
51,926
+1,024
+2% +$81.9K 0.01% 741
2023
Q2 		$3.79M Buy
50,902
+50,410
+10,246% +$2.98M 0.01% 739
2023
Q1 		$26K Sell
492
-543
-52% -$34.4K ﹤0.01% 2706
2022
Q4 		$70K Buy
1,035
+443
+75% +$40.7K ﹤0.01% 2575
2022
Q3 		$74K Buy
+592
New +$70.6K ﹤0.01% 2262

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Mariner's DNA Position: Q2 2026 in Review

Mariner increased its Ginkgo Bioworks (DNA) stake by 12% in Q2 2026, buying an estimated $59K and bringing the position to 67,359 shares worth $667K. The position accounts for ﹤0.01% of the portfolio, ranked #2264.

Mariner first reported a position in DNA in Q3 2022 and has held it in 16 quarters since. The position peaked at $3.79M in Q2 2023. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Mariner held 67,359 shares of Ginkgo Bioworks worth $667K as of Q2 2026.
  • Mariner bought 7,060 Ginkgo Bioworks shares in Q2 2026, an estimated $59K.
  • Ginkgo Bioworks made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2264 holding.
  • Mariner first reported a position in Ginkgo Bioworks in Q3 2022 and has held it in 16 quarters since.
  • Mariner's Ginkgo Bioworks position peaked at $3.79M in Q2 2023.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.